Veuillez utiliser cette adresse pour citer ce document :
https://di.univ-blida.dz/jspui/handle/123456789/25513
Affichage complet
Élément Dublin Core | Valeur | Langue |
---|---|---|
dc.contributor.author | Saoudi, Roufaida | - |
dc.contributor.author | Bachir, Cherif Khadidja | - |
dc.date.accessioned | 2023-10-11T09:36:13Z | - |
dc.date.available | 2023-10-11T09:36:13Z | - |
dc.date.issued | 2023 | - |
dc.identifier.uri | https://di.univ-blida.dz/jspui/handle/123456789/25513 | - |
dc.description | 4.540.1.1123/p68 | fr_FR |
dc.description.abstract | The aim of this work is to develop the galenic form of a generic drug, PERGUS®, in the form of coated immediate-release tablets, based on Prasugrel (active ingredient) at a dose of 10mg. The manufacturing development was carried out successively on powder mixing, dry granulation, grain compaction, grinding, compression and finally tablet coating. Quality control of production intermediates and semi-finished products was carried out in accordance with European pharmacopoeia standards. Pharmaco-technical and physico-chemical tests have shown satisfactory results and compliance with the specifications required by the European Pharmacopoeia. The generic PERGUS® 10mg was successfully developed using a galenic process and reliable, reproducible analytical and biopharmaceutical techniques. | fr_FR |
dc.language.iso | fr | fr_FR |
dc.publisher | blida 1 | fr_FR |
dc.subject | Galenic development, dry granulation, coated tablets, generic drug, quality control, Pharmacopoeia. | fr_FR |
dc.title | Développement de fabrication d’un comprimé Pergus ® 10 mg | fr_FR |
dc.type | Other | fr_FR |
Collection(s) : | Mémoires de Master |
Fichier(s) constituant ce document :
Fichier | Description | Taille | Format | |
---|---|---|---|---|
Mémoire PFE finale of the final for real 2023 (1).pdf | 1,95 MB | Adobe PDF | Voir/Ouvrir |
Tous les documents dans DSpace sont protégés par copyright, avec tous droits réservés.